Volume 139, Issue 6, Pages 1877-1886.e2 (December 2010) Linaclotide Improves Abdominal Pain and Bowel Habits in a Phase IIb Study of Patients With Irritable Bowel Syndrome With Constipation Jeffrey M. Johnston, Caroline B. Kurtz, James E. MacDougall, Bernard J. Lavins, Mark G. Currie, Donald A. Fitch, Chris O'Dea, Mollie Baird, Anthony J. Lembo Gastroenterology Volume 139, Issue 6, Pages 1877-1886.e2 (December 2010) DOI: 10.1053/j.gastro.2010.08.041 Copyright © 2010 AGA Institute Terms and Conditions
Figure 1 Weekly mean change from baseline in CSBM rate (A) and abdominal pain (B) for linaclotide 75, 150, 300, and 600 μg and placebo. Gastroenterology 2010 139, 1877-1886.e2DOI: (10.1053/j.gastro.2010.08.041) Copyright © 2010 AGA Institute Terms and Conditions
Figure 2 Mean abdominal pain (A), abdominal pain in “severe” patients (B), abdominal discomfort (C), and bloating (D) ratings during the 2-week pretreatment baseline and 12-week treatment periods for linaclotide 75, 150, 300, and 600 μg and placebo. Gastroenterology 2010 139, 1877-1886.e2DOI: (10.1053/j.gastro.2010.08.041) Copyright © 2010 AGA Institute Terms and Conditions
Figure 3 Percentage of patients who were (A) adequate relief responders during the 12-week treatment periods and (B) global relief responders during the 12-week treatment period for linaclotide 75, 150, 300, and 600 μg and placebo. Gastroenterology 2010 139, 1877-1886.e2DOI: (10.1053/j.gastro.2010.08.041) Copyright © 2010 AGA Institute Terms and Conditions
Supplementary Figure 1 Diagram of patient flow. Gastroenterology 2010 139, 1877-1886.e2DOI: (10.1053/j.gastro.2010.08.041) Copyright © 2010 AGA Institute Terms and Conditions